All analyses
5 min read

Last updated:

Vitamin D: the claims the large trials allow, and the ones they do not

Twenty-five thousand participants followed for five years, and no reduction in fractures in the general population. Yet the effect exists elsewhere, at a moderate daily dose and in people who are deficient. Here is what the trials really show, and what it changes in coaching.

10 studies citedsee the sources

Benjamin Sant

Co-founder of the School of Longevity

Blood tests and prevention markers
Blood tests and prevention markers

In the general population, supplementation does not reduce fractures

The VITAL trial remains the reference on this question. Twenty-five thousand eight hundred seventy-one American adults, men aged 50 and over, women aged 55 and over, received 2,000 IU of vitamin D3 per day or a placebo for a median of 5.3 years. Participants were not recruited on a criterion of deficiency, low bone mass or osteoporosis. Of the 1,991 confirmed fractures, the hazard ratio is 0.98 for total fractures, 0.97 for non-vertebral fractures and 1.01 for hip fractures. None of these results reaches the significance threshold.

This result does not depend on any subgroup. The authors tested age, sex, origin, body mass index and especially baseline 25-hydroxyvitamin D concentration: no baseline characteristic modifies the effect of treatment. This is the point that surprises practitioners most, because it contradicts the widespread idea that supplementing people with low levels would be enough to obtain a bone benefit.

A 2024 meta-analysis of seven trials and 71,899 people aged 60 and over, without known bone disease, confirms the absence of effect on total fractures, with a relative risk of 1.03. It also notes an unfavorable signal in women, with an increased hip fracture risk, relative risk 1.34 across 164 events against 121. The authors draw an explicit instruction from it: do not prescribe high intermittent doses without calcium in a person over 60 whose vitamin and bone status is unknown.

On falls, dose and rhythm of intake change the result

Falls tell a different story from fractures. A 2024 network meta-analysis, 35 randomized trials and 58,937 participants, with low heterogeneity, finds a reduction in fall risk at 800 to 1,000 IU per day, relative risk 0.85. The same work shows that vitamin D at this dose, with or without calcium, does better than calcium alone.

The rhythm of intake weighs as much as the dose. With daily administration, the reduction reaches 22 percent, relative risk 0.78. With intermittent administration, the preventive effect disappears. And above 1,000 IU per day, fall risk increases compared with the 800 to 1,000 IU range. There is therefore a window, and going beyond it brings nothing, on the contrary.

Baseline status selects the people who get something out of it. The reduction is clear in those whose 25-hydroxyvitamin D is 50 nmol/L or below, relative risk 0.69, and absent above this threshold. In other words, the benefit on falls concentrates on correcting a real deficiency, not on adding a dose to someone who is not lacking.

On cancer, the signal concerns mortality and not incidence

In VITAL, vitamin D did not reduce the incidence of invasive cancers, hazard ratio 0.96, nor major cardiovascular events, hazard ratio 0.97, nor all-cause mortality, hazard ratio 0.99. No excess of hypercalcemia or adverse effect was identified. These figures must be known as they are, because they are regularly presented the other way round.

Cancer mortality is the only signal that holds. In VITAL, the hazard ratio is 0.83, and it strengthens when the first year of follow-up is excluded, 0.79, or the first two, 0.75. An individual data meta-analysis from 2023, 14 trials and 104,727 participants, finds a non-significant 6 percent decrease overall, relative risk 0.94.

The detail matters more than the overall result. In this same meta-analysis, the ten trials with daily intake show a 12 percent decrease in cancer mortality, relative risk 0.88, while the four bolus trials show no benefit, relative risk 1.07, with a statistically significant interaction. People aged 70 and over seem to benefit most. Regularity of intake, not the quantity delivered, is therefore the factor that separates positive from negative trials.

The 2024 guideline moves the question from dosage to age

The American endocrinology society published a guideline in 2024 built with the GRADE method, giving priority to randomized trials. Its conclusion is that supplementation reduces rickets and respiratory infections in children, mortality in people aged 75 and over, pregnancy complications and progression from prediabetes to diabetes.

It draws an empirical supplementation recommendation for four populations: those aged 1 to 18, those aged 75 and over, pregnant women and people with prediabetes. Empirical here means an intake above reference intakes, implemented without prior assay of 25-hydroxyvitamin D. This is a reversal compared with usual practice, which assays first and decides afterwards.

A critical appraisal published in 2026 welcomes the methodological rigor but points out what the text leaves open: poorly specified doses, applicability debated for certain populations, a contradiction with earlier guidelines, and poorly settled consequences for the use of biological assay. A recent and solid guideline therefore does not close the question, and that must be said to a person who arrives with their assay in hand.

In routine practice, the error goes both ways

A 2025 European cross-sectional analysis, conducted in four countries on 2,008 patients with a mean age of 79.4, all with multiple conditions and on at least five medications, measures the gap between the rule and reality. Forty-one percent were receiving vitamin D.

One third of patients had an underuse of supplementation with regard to validated prescribing criteria, that is 33.9 percent of the whole and nearly 70 percent of those not receiving it. The criteria retained were high-risk situations: prolonged systemic corticosteroid therapy, known osteoporosis or osteopenia, history of fragility fracture, confinement at home, institutionalization, or repeated falls.

At the other end, 10.2 percent received potentially inappropriate supplementation, that is a quarter of supplemented people. The number of medications works both ways: the more it increases, the less frequent the underuse, and the more frequent the excess. Advanced age and male sex are associated with underuse. The problem is therefore not a global lack of vitamin D, it is faulty targeting.

The consequences for a practitioner, and the limit of their role

The first consequence is to stop presenting vitamin D as general bone protection. In an autonomous adult, without documented deficiency, without osteoporosis and without fracture history, the data do not support an expectation on fractures. Saying it clearly avoids a disappointment and preserves the credibility of the rest of the coaching.

The second is to identify the high-risk situations described above, because they are the ones studies retain and practice most often misses. Spotting prolonged corticosteroid therapy, a history of fragility fracture, confinement at home or repeated falls is part of a practitioner's history taking, and leads to referral to the treating physician, who alone decides on dosage and prescription.

The third concerns rhythm more than quantity. The positive trials on falls and on cancer mortality are trials with moderate daily intake, and trials with high spaced doses are neutral or unfavorable. A person who receives a quarterly ampoule and believes they are covered deserves to have this difference explained, then to be sent back to their physician. Vitamin D illustrates a broader principle: a supplement is only of interest if it corrects an identified deficit, which holds for all the supplements described as anti-aging, and is read in a biological assessment interpreted with method.

Sources

  1. 1.Manson JE, et al. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. N Engl J Med. 2019.
  2. 2.LeBoff MS, et al. Supplemental Vitamin D and Incident Fractures in Midlife and Older Adults. N Engl J Med. 2022.
  3. 3.Tan L, et al. Effect of vitamin D, calcium, or combined supplementation on fall prevention: a systematic review and updated network meta-analysis. BMC Geriatr. 2024.
  4. 4.Kuznia S, et al. Efficacy of vitamin D3 supplementation on cancer mortality: Systematic review and individual patient data meta-analysis of randomised controlled trials. Ageing Res Rev. 2023.
  5. 5.Manson JE, et al. Principal results of the VITamin D and OmegA-3 TriaL (VITAL) and updated meta-analyses of relevant vitamin D trials. J Steroid Biochem Mol Biol. 2020.
  6. 6.de Souza MM, et al. Vitamin D Supplementation and the Incidence of Fractures in the Elderly Healthy Population: A Meta-analysis of Randomized Controlled Trials. J Gen Intern Med. 2024.
  7. 7.Pilz S, et al. The 2024 Endocrine Society Guideline on Vitamin D: Comprehensive Summary and Critical Appraisal. Nutrients. 2026.
  8. 8.Moutzouri E, et al. Inappropriate vitamin D supplementation among multimorbid older patients: a multicountry analysis. BMC Geriatr. 2025.
  9. 9.Wei FL, et al. Association Between Vitamin D Supplementation and Fall Prevention. Front Endocrinol (Lausanne). 2022.
  10. 10.Mendez-Sanchez L, et al. Calcium and vitamin D for increasing bone mineral density in premenopausal women. Cochrane Database Syst Rev. 2023.

Reading studies is one thing, turning them into a plan is another

The Longevity Practitioner certification teaches the method that turns this kind of data into an accompaniment decision: assess, prioritise, plan over 90 days, re-measure, and know when to hand over.

See the certification

11 modules, €2,200. Enrol

Benjamin Sant

Co-founder of the School of Longevity

Cofounder of the School of Longevity with Tristan Maruyama. A former officer trained at Saint-Cyr from 2019 to 2022 and a coach since 2018, he has supported more than 4,000 people. He leads the School's editorial content with one constant principle: pass on only what can be situated, verified and applied seriously.

This article is published for information and education. It does not replace medical advice. For any personal health question, consult a healthcare professional.